Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLB-A04
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal (preclinical And Animal Studies Only)
01
Overview
GLB-A04 is a chemically modified DNA aptamer developed to specifically target phosphorylated AXL receptor tyrosine kinase (phospho-AXL), a protein implicated in cancer progression and metastasis, particularly in ovarian cancer. Through backbone modifications such as thiophosphate/dithiophosphate and polyethylene glycol conjugation at the 5' end, GLB-A04 demonstrates enhanced stability, bioavailability, and prolonged antitumor activity in preclinical models. In orthotopic mouse models of ovarian cancer, GLB-A04 administration resulted in significantly reduced tumor growth and metastasis. Its optimized design allows for sustained AXL inhibition at low doses, supporting further translational development as a targeted therapy for drug-resistant or metastatic ovarian cancer[2][4].
- Other names
- phospho-AXL modulators
02
Targets
AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on GLB-A04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLB-A04.